• +1-646-491-9876
    • +91-20-67278686

    Search

    Hepatitis C - Pipeline Review, H1 2015

    Hepatitis C - Pipeline Review, H1 2015

    • Report Code ID: RW0001172443
    • Category Pharmaceuticals
    • No. of Pages 639
    • Publication Month Jan-15
    • Publisher Name Global Markets Direct
    Hepatitis C-Pipeline Review, H1 2015

    Summary

    Publisher's, 'Hepatitis C-Pipeline Review, H1 2015', provides an overview of the Hepatitis C's therapeutic pipeline.

    This report provides comprehensive information on the therapeutic development for Hepatitis C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis C and special features on late-stage and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

    The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

    Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

    Scope

    - The report provides a snapshot of the global therapeutic landscape of Hepatitis C
    - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in the therapeutics development for Hepatitis C and enlists all their major and minor projects
    - The report summarizes all the dormant and discontinued pipeline projects
    - A review of the Hepatitis C products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - A detailed assessment of monotherapy and combination therapy pipeline projects
    - Coverage of the Hepatitis C pipeline on the basis of target, MoA, route of administration and molecule type
    - Latest news and deals relating related to pipeline products

    Reasons to buy

    - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Identify and understand important and diverse types of therapeutics under development for Hepatitis C
    - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
    - Devise corrective measures for pipeline projects by understanding Hepatitis C pipeline depth and focus of Indication therapeutics
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
    Table of Contents
    Table of Contents 2
    List of Tables 12
    List of Figures 16
    Introduction 17
    Global Markets Direct Report Coverage 17
    Hepatitis C Overview 18
    Therapeutics Development 19
    Pipeline Products for Hepatitis C-Overview 19
    Pipeline Products for Hepatitis C-Comparative Analysis 20
    Hepatitis C-Therapeutics under Development by Companies 21
    Hepatitis C-Therapeutics under Investigation by Universities/Institutes 30
    Hepatitis C-Pipeline Products Glance 33
    Late Stage Products 33
    Clinical Stage Products 34
    Early Stage Products 35
    Unknown Stage Products 36
    Hepatitis C-Products under Development by Companies 37
    Hepatitis C-Products under Investigation by Universities/Institutes 52
    Hepatitis C-Companies Involved in Therapeutics Development 55
    3-V Biosciences, Inc. 55
    AbbVie Inc. 56
    Achillion Pharmaceuticals, Inc. 57
    Adaptimmune Limited 58
    AiCuris GmbH & Co. KG 59
    AIMM Therapeutics B.V. 60
    Akshaya Bio Inc. 61
    Alnylam Pharmaceuticals, Inc. 62
    Altor BioScience Corporation 63
    Amarna Therapeutics B.V. 64
    American Gene Technologies International Inc. 65
    Anacor Pharmaceuticals, Inc. 66
    ARA Healthcare Pvt. Ltd. 67
    Arrowhead Research Corporation 68
    Ascendis Pharma A/S 69
    Astex Pharmaceuticals, Inc. 70
    Biogenomics Limited 71
    BioLineRx, Ltd. 72
    Bionor Pharma ASA 73
    Biotest AG 74
    Biotron Limited 75
    Bolder Biotechnology, Inc. 76
    Bristol-Myers Squibb Company 77
    Celgene Corporation 78
    Chiasma, Inc. 79
    Chugai Pharmaceutical Co., Ltd. 80
    Cocrystal Pharma, Inc. 81
    Conatus Pharmaceuticals Inc. 82
    Crucell N.V. 83
    Debiopharm International S.A. 84
    DEKK-TEC, Inc. 85
    Delpor, Inc. 86
    Digna Biotech, S.L. 87
    DiscoveryBiomed, Inc. 88
    Enanta Pharmaceuticals, Inc. 89
    F. Hoffmann-La Roche Ltd. 90
    Genecode AS 91
    GeneCure LLC 92
    Gilead Sciences, Inc. 93
    GlaxoSmithKline plc 94
    HanAll Biopharma Co., Ltd. 95
    Hanmi Pharmaceuticals, Co. Ltd. 96
    HEC Pharm Co., Ltd. 97
    Hepacyl Therapeutics, SL 98
    Hependo Sp. z o. o. (Ltd) 99
    Hetero Drugs Limited 100
    Humabs BioMed SA 101
    ImmunoBiology Ltd. 102
    Immunocore Limited 103
    Immunomedics, Inc. 104
    Immunotech Laboratories, Inc. 105
    Inbiopro Solutions Pvt. Ltd. 106
    Inovio Pharmaceuticals, Inc. 107
    Integrated BioTherapeutics, Inc. 108
    iTherX, Inc. 109
    Johnson & Johnson 110
    Kineta, Inc. 111
    Koronis Pharma, Inc. 112
    LG Life Sciences, Ltd. 113
    Ligand Pharmaceuticals, Inc. 114
    Meda AB 115
    Medivir AB 116
    Merck & Co., Inc. 117
    Microbio Co., Ltd. 118
    Microbiotix, Inc. 119
    Myelo Therapeutics GmbH 120
    Novartis AG 121
    Oncolys BioPharma Inc. 122
    Ono Pharmaceutical Co., Ltd. 123
    Peregrine Pharmaceuticals, Inc. 124
    Pfenex Inc. 125
    Pfizer Inc. 126
    PharmaEssentia Corporation 127
    Polaris Pharmaceuticals, Inc. 128
    Presidio Pharmaceuticals, Inc. 129
    Profectus BioSciences, Inc. 130
    Quintessence Biosciences, Inc. 131
    Regulus Therapeutics Inc. 132
    RFS Pharma, LLC 133
    Rodos BioTarget GmbH 134
    Romark Laboratories, L.C. 135
    Seek 136
    SelectX Pharmaceuticals, Inc. 137
    SKAU Vaccines ApS 138
    SomaGenics Inc. 139
    Sorrento Therapeutics, Inc. 140
    Spring Bank Pharmaceuticals, Inc. 141
    StemCells, Inc. 142
    Summit Corporation plc 143
    Tacere Therapeutics, Inc. 144
    TaiGen Biotechnology Co., Ltd. 145
    Therapure Biopharma Inc. 146
    Theravectys S.A. 147
    Transgene SA 148
    United Therapeutics Corporation 149
    Vakzine Projekt Management GmbH 150
    Vaxeal Holding SA 151
    VBI Vaccines 152
    Vertex Pharmaceuticals Incorporated 153
    ViroLogik GmbH 154
    WaterStone Pharmaceuticals, Inc. 155
    WhanIn Pharmaceutical Co., Ltd. 156
    Xenetic Biosciences plc 157
    Hepatitis C-Therapeutics Assessment 158
    Assessment by Monotherapy Products 158
    Assessment by Combination Products 159
    Assessment by Target 160
    Assessment by Mechanism of Action 166
    Assessment by Route of Administration 170
    Assessment by Molecule Type 172
    Drug Profiles 174
    (asunaprevir + daclatasvir)-Drug Profile 174
    (daclatasvir + asunaprevir + beclabuvir)-Drug Profile 176
    (danoprevir + ritonavir)-Drug Profile 178
    (grazoprevir + elbasvir)-Drug Profile 179
    (ledipasvir + sofosbuvir)-Drug Profile 181
    (ombitasvir + paritaprevir + ritonavir) + dasabuvir-Drug Profile 184
    (paritaprevir + ritonavir + ombitasvir)-Drug Profile 187
    (ribavirin + hydroxychloroquine)-Drug Profile 189
    (sofosbuvir + GS-5816)-Drug Profile 190
    ABT-493-Drug Profile 192
    ABT-493 + ABT-530-Drug Profile 193
    ABT-530-Drug Profile 195
    ACH-3080-Drug Profile 196
    ACH-3102-Drug Profile 197
    ACH-3107-Drug Profile 198
    ACH-3422-Drug Profile 199
    ACP-007-Drug Profile 200
    AG-1104-Drug Profile 201
    AIC-649-Drug Profile 202
    AL-335-Drug Profile 203
    AL-516-Drug Profile 204
    alisporivir-Drug Profile 205
    Antiviral TCR-Ck-Drug Profile 207
    Antiviral TCR-Ig-Drug Profile 208
    ARABS-3-Drug Profile 209
    ARABS-4-Drug Profile 210
    ARABS-5-Drug Profile 211
    asunaprevir-Drug Profile 212
    AT-26893-Drug Profile 214
    AV-4025-Drug Profile 215
    AV-4203-Drug Profile 217
    AVL-181-Drug Profile 218
    AVL-192-Drug Profile 219
    AVR-560-Drug Profile 220
    bavituximab-Drug Profile 221
    BBT-012-Drug Profile 226
    beclabuvir-Drug Profile 227
    BIT-225-Drug Profile 229
    BIT-314-Drug Profile 231
    BL-8030-Drug Profile 232
    BZF-961-Drug Profile 233
    CDI-244-Drug Profile 234
    Cell Therapy for HCV/Diabetes-Drug Profile 235
    CIGB-230-Drug Profile 236
    CPI-43132-Drug Profile 238
    Creaferon-Drug Profile 239
    daclatasvir dihydrochloride-Drug Profile 240
    DAG-181-Drug Profile 242
    danoprevir-Drug Profile 243
    dasabuvir-Drug Profile 245
    DCBF-1-Drug Profile 247
    deldeprevir-Drug Profile 248
    Dendritic Cell Therapy for Hepatitis C-Drug Profile 249
    Dimethylpyridine-Drug Profile 250
    DL-2014-Drug Profile 251
    DLP-201-Drug Profile 252
    Drug for Hepatitis C Infections-Drug Profile 253
    Drug for Infectious Diseases-Drug Profile 254
    Drugs for HCV Infection-Drug Profile 255
    Drugs to Antagonize Type I Interferon Receptor for Viral Infections-Drug Profile 256
    Drugs to Inhibit NS5B for Hepatitis C-Drug Profile 257
    E-2216-Drug Profile 258
    EDP-239-Drug Profile 259
    EDP-239 + alisporivir-Drug Profile 260
    EDP-546-Drug Profile 261
    elbasvir-Drug Profile 262
    emricasan-Drug Profile 263
    Fluoropyridone-19-Drug Profile 265
    furaprevir-Drug Profile 266
    Gene Therapy for Hepatitis B and Hepatitis C-Drug Profile 267
    Gene Therapy for Hepatitis C-Drug Profile 268
    grazoprevir-Drug Profile 269
    GS-563253-Drug Profile 271
    GS-5816-Drug Profile 272
    GS-9256-Drug Profile 273
    GS-9620-Drug Profile 274
    GS-9669-Drug Profile 276
    GS-9857-Drug Profile 277
    GSK-2878175-Drug Profile 278
    H-31356-Drug Profile 279
    H-5C-Drug Profile 280
    H-5CN-Drug Profile 282
    Haprolid-Drug Profile 284
    hepatitis C [Type 1, 6] vaccine-Drug Profile 285
    hepatitis C immune globulin (human)-Drug Profile 286
    hepatitis C vaccine-Drug Profile 288
    hepatitis C vaccine-Drug Profile 289
    hepatitis C vaccine-Drug Profile 290
    hepatitis C vaccine-Drug Profile 291
    hepatitis C vaccine-Drug Profile 292
    hepatitis C vaccine-Drug Profile 293
    hepatitis C vaccine-Drug Profile 294
    hepatitis C vaccine-Drug Profile 295
    hepatitis C vaccine-Drug Profile 296
    hepatitis C Vaccine (H77)-Drug Profile 297
    HepBioVax-Drug Profile 298
    HL-143-Drug Profile 299
    hLEC-Drug Profile 300
    HM-10660A-Drug Profile 302
    IBPB-006IA-Drug Profile 303
    ID-12-Drug Profile 304
    ID-4025-Drug Profile 305
    IkT-064-Drug Profile 306
    InferoXen-Drug Profile 307
    Innate Immune Agonists-Drug Profile 308
    INO-8000-Drug Profile 309
    interferon alfa-2a (recombinant)-Drug Profile 310
    interferon alfa-2a SR-Drug Profile 311
    interferon alfa-2b-Drug Profile 312
    interferon alfa-2b (recombinant)-Drug Profile 313
    Interferon Alfa-5-Drug Profile 314
    Interferon Lambda-1 Linked Fab Dimer-Drug Profile 315
    ITV-1-Drug Profile 316
    ITX-4520-Drug Profile 317
    ITX-5061-Drug Profile 318
    JNJ-42039556-Drug Profile 320
    JNJ-47910382-Drug Profile 322
    JNJ-56914845-Drug Profile 323
    JT-16-Drug Profile 325
    KW-2-Drug Profile 326
    KW-5-Drug Profile 327
    LCTA-949-Drug Profile 328
    LG-7501-Drug Profile 329
    MB-110-Drug Profile 330
    MBL-HCV-1-Drug Profile 331
    MBX-700-Drug Profile 332
    MBX-701-Drug Profile 333
    mericitabine-Drug Profile 334
    miglustat-Drug Profile 336
    miravirsen-Drug Profile 337
    MIV-802-Drug Profile 339
    MK-2248-Drug Profile 340
    MK-2748-Drug Profile 341
    MK-3682-Drug Profile 342
    MK-7680-Drug Profile 343
    MK-8408-Drug Profile 344
    MK-8876-Drug Profile 345
    Monoclonal Antibodies for Hepatitis C-Drug Profile 346
    Monoclonal Antibodies for Hepatitis C-Drug Profile 347
    Monoclonal Antibodies to Inhibit E2 Glycoprotein for HCV-Drug Profile 348
    Monoclonal Antibodies to Inhibit Viral E1/E2 Proteins for Hepatitis C-Drug Profile 349
    Monoclonal Antibody for Hepatitis C-Drug Profile 350
    Monoclonal Antibody for Hepatitis C-Drug Profile 351
    Monoclonal Antibody for Hepatitis C-Drug Profile 352
    Monoclonal Antibody for Hepatitis C Infection-Drug Profile 353
    Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases-Drug Profile 354
    Monoclonal Antibody to Inhibit HCV Envelope Protein E2 for Hepatitis C-Drug Profile 356
    Myelo-001-Drug Profile 357
    N-251-Drug Profile 358
    N-89-Drug Profile 359
    NA-255-Drug Profile 360
    narlaprevir-Drug Profile 361
    NICAM Program-Drug Profile 362
    NICAM-44002-Drug Profile 364
    nitazoxanide SR-Drug Profile 366
    nivocasan-Drug Profile 368
    nivolumab (recombinant)-Drug Profile 370
    NVP-018-Drug Profile 375
    OBPAI-001-Drug Profile 376
    ombitasvir-Drug Profile 377
    oncostatin M-Drug Profile 378
    paritaprevir-Drug Profile 379
    PEG-IFN-SA-Drug Profile 381
    pegargiminase-Drug Profile 382
    peginterferon alfa-2a-Drug Profile 386
    peginterferon alfa-2a (recombinant)-Drug Profile 387
    peginterferon alfa-2b-Drug Profile 388
    peginterferon lambda-1a-Drug Profile 390
    Peptide to Inhibit FOXP3 for Hepatitis and Oncology-Drug Profile 391
    Peptides to Inhibit NS4B, 5A and 5B for Hepatitis C-Drug Profile 392
    PPI-383-Drug Profile 393
    PPI-668-Drug Profile 394
    ProCvax-Drug Profile 396
    Protein for Hepatitis C, Hepatitis B and Cancer-Drug Profile 397
    Proteins to Inhibit NS3 Protease for Hepatitis C-Drug Profile 398
    PTC-512-Drug Profile 399
    PTC-725-Drug Profile 400
    PTC-971-Drug Profile 401
    RBT-05-Drug Profile 402
    Recombinant Enzyme for Hepatitis C-Drug Profile 403
    Recombinant Protein for HCV-Drug Profile 404
    Recombinant Proteins for HCV infection-Drug Profile 405
    RG-101-Drug Profile 406
    RG-7109-Drug Profile 409
    RNAi Oligonucleotide for Hepatitis C-Drug Profile 410
    RNAi Oligonucleotide to Inhibit MicroRNA-122 for Hepatitis C-Drug Profile 411
    RNAi Oligonucleotide to Target miR-122 for Hepatitis C-Drug Profile 413
    RNAi Oligonucleotides for Hepatitis C-Drug Profile 414
    rOAS-Drug Profile 415
    RS-1137-Drug Profile 416
    RS-1142-Drug Profile 417
    RS-1145-Drug Profile 418
    RS-930-Drug Profile 419
    RS-961-Drug Profile 420
    samatasvir-Drug Profile 421
    SB-9200-Drug Profile 423
    SCY-635-Drug Profile 425
    setrobuvir-Drug Profile 427
    silibinin-Drug Profile 429
    SIRNA-034-Drug Profile 430
    Small Molecule for Hepatitis C-Drug Profile 431
    Small Molecule for Viral Diseases-Drug Profile 432
    Small Molecule to Antagonize EGFR for Hepatitis C-Drug Profile 433
    Small Molecule to Inhibit Cyclophilin for Hepatitis C-Drug Profile 434
    Small Molecule to Inhibit Fatty Acid Synthase for Viral Infections-Drug Profile 435
    Small Molecule to Inhibit HCV Polymerase for Hepatitis C-Drug Profile 436
    Small Molecule to Inhibit NS4B Protein for HCV-Drug Profile 437
    Small Molecule to Inhibit NS5A for HCV-Drug Profile 438
    Small Molecule to Inhibit NS5A for Hepatitis C-Drug Profile 439
    Small Molecule to Inhibit NS5A for Hepatitis C Infections-Drug Profile 440
    Small Molecule to Inhibit NS5B Polymerase for Hepatitis C-Drug Profile 441
    Small Molecule to Inhibit RPS25 for Hepatitis C-Drug Profile 442
    Small Molecule to Inhibit Viral RNA for Hepatitis C-Drug Profile 443
    Small Molecules for Hepatitis C-Drug Profile 444
    Small Molecules for Hepatitis C-Drug Profile 445
    Small Molecules for Hepatitis C-Drug Profile 446
    Small Molecules for Herpes Simplex and Hepatitis C Infections-Drug Profile 447
    Small Molecules to Activate AMPK for Hepatitis C-Drug Profile 448
    Small Molecules to Inhibit NS3 Helicase for Hepatitis C-Drug Profile 449
    Small Molecules to Inhibit NS3 Protease and RNA Helicase for Hepatitis C-Drug Profile 450
    Small Molecules to Inhibit NS3 Protease for Hepatitis C-Drug Profile 451
    Small Molecules to Inhibit NS3 Protease for Hepatitis C-Drug Profile 452
    Small Molecules to Inhibit NS3/4A Protease for Hepatitis C-Drug Profile 453
    Small Molecules to Inhibit NS3/4A Serine Protease for Hepatitis C-Drug Profile 454
    Small Molecules to inhibit NS5B Polymerase for HCV-Drug Profile 455
    Small Molecules to Inhibit NS5B Polymerase for Hepatitis C-Drug Profile 456
    Small Molecules to Inhibit NS5B Polymerase for Hepatitis C Virus Infection-Drug Profile 457
    Small Molecules to Inhibit PI4KIIIbeta for HCV-Drug Profile 458
    Small Molecules to Inhibit RNA Polymerase for Hepatitis C-Drug Profile 459
    Small Molecules to Inhibit Viral Fusion for HIV, HCV and Influenza-Drug Profile 460
    Small Molecules to Target Heparan Sulphate Proteoglycan for Bacterial and Viral Infections-Drug Profile 461
    Small Molecules to Target IRES RNA for HCV Infection-Drug Profile 462
    sofosbuvir-Drug Profile 463
    sovaprevir-Drug Profile 466
    Synthetic Peptide for Hepatitis C-Drug Profile 468
    Synthetic Peptides to Inhibit E1 and E2 Glycoprotein for HCV-Drug Profile 469
    Synthetic Peptides to Inhibit Hsp70 for Hepatitis C-Drug Profile 470
    TBI-301-Drug Profile 471
    TD-6450-Drug Profile 472
    telaprevir-Drug Profile 473
    TerCvax-Drug Profile 477
    TG-4040-Drug Profile 479
    thrombopoietin-Drug Profile 482
    TT-033-Drug Profile 483
    TT-034-Drug Profile 484
    TVB-2640-Drug Profile 486
    Vacc-HCV-Drug Profile 487
    Vaccine to Target TLR2 for Infectious Disease-Drug Profile 488
    vedroprevir-Drug Profile 489
    VL-01-Drug Profile 490
    VPM-5001-Drug Profile 491
    Hepatitis C-Recent Pipeline Updates 492
    Hepatitis C-Dormant Projects 585
    Hepatitis C-Discontinued Products 604
    Hepatitis C-Product Development Milestones 612
    Featured News & Press Releases 612
    Appendix 621
    Methodology 621
    Coverage 621
    Secondary Research 621
    Primary Research 621
    Expert Panel Validation 621
    Contact Us 622
    Disclaimer 622



    List of Tables
    Number of Products under Development for Hepatitis C, H1 2015 36
    Number of Products under Development for Hepatitis C-Comparative Analysis, H1 2015 37
    Number of Products under Development by Companies, H1 2015 39
    Number of Products under Development by Companies, H1 2015 (Contd..1) 40
    Number of Products under Development by Companies, H1 2015 (Contd..2) 41
    Number of Products under Development by Companies, H1 2015 (Contd..3) 42
    Number of Products under Development by Companies, H1 2015 (Contd..4) 43
    Number of Products under Development by Companies, H1 2015 (Contd..5) 44
    Number of Products under Development by Companies, H1 2015 (Contd..6) 45
    Number of Products under Development by Companies, H1 2015 (Contd..7) 46
    Number of Products under Investigation by Universities/Institutes, H1 2015 48
    Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 49
    Comparative Analysis by Late Stage Development, H1 2015 50
    Comparative Analysis by Clinical Stage Development, H1 2015 51
    Comparative Analysis by Early Stage Development, H1 2015 52
    Comparative Analysis by Unknown Stage Development, H1 2015 53
    Products under Development by Companies, H1 2015 54
    Products under Development by Companies, H1 2015 (Contd..1) 55
    Products under Development by Companies, H1 2015 (Contd..2) 56
    Products under Development by Companies, H1 2015 (Contd..3) 57
    Products under Development by Companies, H1 2015 (Contd..4) 58
    Products under Development by Companies, H1 2015 (Contd..5) 59
    Products under Development by Companies, H1 2015 (Contd..6) 60
    Products under Development by Companies, H1 2015 (Contd..7) 61
    Products under Development by Companies, H1 2015 (Contd..8) 62
    Products under Development by Companies, H1 2015 (Contd..9) 63
    Products under Development by Companies, H1 2015 (Contd..10) 64
    Products under Development by Companies, H1 2015 (Contd..11) 65
    Products under Development by Companies, H1 2015 (Contd..12) 66
    Products under Development by Companies, H1 2015 (Contd..13) 67
    Products under Development by Companies, H1 2015 (Contd..14) 68
    Products under Investigation by Universities/Institutes, H1 2015 69
    Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 70
    Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 71
    Hepatitis C-Pipeline by 3-V Biosciences, Inc., H1 2015 72
    Hepatitis C-Pipeline by AbbVie Inc., H1 2015 73
    Hepatitis C-Pipeline by Achillion Pharmaceuticals, Inc., H1 2015 74
    Hepatitis C-Pipeline by Adaptimmune Limited, H1 2015 75
    Hepatitis C-Pipeline by AiCuris GmbH & Co. KG, H1 2015 76
    Hepatitis C-Pipeline by AIMM Therapeutics B.V., H1 2015 77
    Hepatitis C-Pipeline by Akshaya Bio Inc., H1 2015 78
    Hepatitis C-Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015 79
    Hepatitis C-Pipeline by Altor BioScience Corporation, H1 2015 80
    Hepatitis C-Pipeline by Amarna Therapeutics B.V., H1 2015 81
    Hepatitis C-Pipeline by American Gene Technologies International Inc., H1 2015 82
    Hepatitis C-Pipeline by Anacor Pharmaceuticals, Inc., H1 2015 83
    Hepatitis C-Pipeline by ARA Healthcare Pvt. Ltd., H1 2015 84
    Hepatitis C-Pipeline by Arrowhead Research Corporation, H1 2015 85
    Hepatitis C-Pipeline by Ascendis Pharma A/S, H1 2015 86
    Hepatitis C-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 87
    Hepatitis C-Pipeline by Biogenomics Limited, H1 2015 88
    Hepatitis C-Pipeline by BioLineRx, Ltd., H1 2015 89
    Hepatitis C-Pipeline by Bionor Pharma ASA, H1 2015 90
    Hepatitis C-Pipeline by Biotest AG, H1 2015 91
    Hepatitis C-Pipeline by Biotron Limited, H1 2015 92
    Hepatitis C-Pipeline by Bolder Biotechnology, Inc., H1 2015 93
    Hepatitis C-Pipeline by Bristol-Myers Squibb Company, H1 2015 94
    Hepatitis C-Pipeline by Celgene Corporation, H1 2015 95
    Hepatitis C-Pipeline by Chiasma, Inc., H1 2015 96
    Hepatitis C-Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2015 97
    Hepatitis C-Pipeline by Cocrystal Pharma, Inc., H1 2015 98
    Hepatitis C-Pipeline by Conatus Pharmaceuticals Inc., H1 2015 99
    Hepatitis C-Pipeline by Crucell N.V., H1 2015 100
    Hepatitis C-Pipeline by Debiopharm International S.A., H1 2015 101
    Hepatitis C-Pipeline by DEKK-TEC, Inc., H1 2015 102
    Hepatitis C-Pipeline by Delpor, Inc., H1 2015 103
    Hepatitis C-Pipeline by Digna Biotech, S.L., H1 2015 104
    Hepatitis C-Pipeline by DiscoveryBiomed, Inc., H1 2015 105
    Hepatitis C-Pipeline by Enanta Pharmaceuticals, Inc., H1 2015 106
    Hepatitis C-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 107
    Hepatitis C-Pipeline by Genecode AS, H1 2015 108
    Hepatitis C-Pipeline by GeneCure LLC, H1 2015 109
    Hepatitis C-Pipeline by Gilead Sciences, Inc., H1 2015 110
    Hepatitis C-Pipeline by GlaxoSmithKline plc, H1 2015 111
    Hepatitis C-Pipeline by HanAll Biopharma Co., Ltd., H1 2015 112
    Hepatitis C-Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 113
    Hepatitis C-Pipeline by HEC Pharm Co., Ltd., H1 2015 114
    Hepatitis C-Pipeline by Hepacyl Therapeutics, SL, H1 2015 115
    Hepatitis C-Pipeline by Hependo Sp. z o. o. (Ltd), H1 2015 116
    Hepatitis C-Pipeline by Hetero Drugs Limited, H1 2015 117
    Hepatitis C-Pipeline by Humabs BioMed SA, H1 2015 118
    Hepatitis C-Pipeline by ImmunoBiology Ltd., H1 2015 119
    Hepatitis C-Pipeline by Immunocore Limited, H1 2015 120
    Hepatitis C-Pipeline by Immunomedics, Inc., H1 2015 121
    Hepatitis C-Pipeline by Immunotech Laboratories, Inc., H1 2015 122
    Hepatitis C-Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 123
    Hepatitis C-Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 124
    Hepatitis C-Pipeline by Integrated BioTherapeutics, Inc., H1 2015 125
    Hepatitis C-Pipeline by iTherX, Inc., H1 2015 126
    Hepatitis C-Pipeline by Johnson & Johnson, H1 2015 127
    Hepatitis C-Pipeline by Kineta, Inc., H1 2015 128
    Hepatitis C-Pipeline by Koronis Pharma, Inc., H1 2015 129
    Hepatitis C-Pipeline by LG Life Sciences, Ltd., H1 2015 130
    Hepatitis C-Pipeline by Ligand Pharmaceuticals, Inc., H1 2015 131
    Hepatitis C-Pipeline by Meda AB, H1 2015 132
    Hepatitis C-Pipeline by Medivir AB, H1 2015 133
    Hepatitis C-Pipeline by Merck & Co., Inc., H1 2015 134
    Hepatitis C-Pipeline by Microbio Co., Ltd., H1 2015 135
    Hepatitis C-Pipeline by Microbiotix, Inc., H1 2015 136
    Hepatitis C-Pipeline by Myelo Therapeutics GmbH, H1 2015 137
    Hepatitis C-Pipeline by Novartis AG, H1 2015 138
    Hepatitis C-Pipeline by Oncolys BioPharma Inc., H1 2015 139
    Hepatitis C-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 140
    Hepatitis C-Pipeline by Peregrine Pharmaceuticals, Inc., H1 2015 141
    Hepatitis C-Pipeline by Pfenex Inc., H1 2015 142
    Hepatitis C-Pipeline by Pfizer Inc., H1 2015 143
    Hepatitis C-Pipeline by PharmaEssentia Corporation, H1 2015 144
    Hepatitis C-Pipeline by Polaris Pharmaceuticals, Inc., H1 2015 145
    Hepatitis C-Pipeline by Presidio Pharmaceuticals, Inc., H1 2015 146
    Hepatitis C-Pipeline by Profectus BioSciences, Inc., H1 2015 147
    Hepatitis C-Pipeline by Quintessence Biosciences, Inc., H1 2015 148
    Hepatitis C-Pipeline by Regulus Therapeutics Inc., H1 2015 149
    Hepatitis C-Pipeline by RFS Pharma, LLC, H1 2015 150
    Hepatitis C-Pipeline by Rodos BioTarget GmbH, H1 2015 151
    Hepatitis C-Pipeline by Romark Laboratories, L.C., H1 2015 152
    Hepatitis C-Pipeline by Seek, H1 2015 153
    Hepatitis C-Pipeline by SelectX Pharmaceuticals, Inc., H1 2015 154
    Hepatitis C-Pipeline by SKAU Vaccines ApS, H1 2015 155
    Hepatitis C-Pipeline by SomaGenics Inc., H1 2015 156
    Hepatitis C-Pipeline by Sorrento Therapeutics, Inc., H1 2015 157
    Hepatitis C-Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2015 158
    Hepatitis C-Pipeline by StemCells, Inc., H1 2015 159
    Hepatitis C-Pipeline by Summit Corporation plc, H1 2015 160
    Hepatitis C-Pipeline by Tacere Therapeutics, Inc., H1 2015 161
    Hepatitis C-Pipeline by TaiGen Biotechnology Co., Ltd., H1 2015 162
    Hepatitis C-Pipeline by Therapure Biopharma Inc., H1 2015 163
    Hepatitis C-Pipeline by Theravectys S.A., H1 2015 164
    Hepatitis C-Pipeline by Transgene SA, H1 2015 165
    Hepatitis C-Pipeline by United Therapeutics Corporation, H1 2015 166
    Hepatitis C-Pipeline by Vakzine Projekt Management GmbH, H1 2015 167
    Hepatitis C-Pipeline by Vaxeal Holding SA, H1 2015 168
    Hepatitis C-Pipeline by VBI Vaccines, H1 2015 169
    Hepatitis C-Pipeline by Vertex Pharmaceuticals Incorporated, H1 2015 170
    Hepatitis C-Pipeline by ViroLogik GmbH, H1 2015 171
    Hepatitis C-Pipeline by WaterStone Pharmaceuticals, Inc., H1 2015 172
    Hepatitis C-Pipeline by WhanIn Pharmaceutical Co., Ltd., H1 2015 173
    Hepatitis C-Pipeline by Xenetic Biosciences plc, H1 2015 174
    Assessment by Monotherapy Products, H1 2015 175
    Assessment by Combination Products, H1 2015 176
    Number of Products by Stage and Target, H1 2015 178
    Number of Products by Stage and Mechanism of Action, H1 2015 184
    Number of Products by Stage and Route of Administration, H1 2015 188
    Number of Products by Stage and Molecule Type, H1 2015 190
    Hepatitis C Therapeutics-Recent Pipeline Updates, H1 2015 509
    Hepatitis C-Dormant Projects, H1 2015 602
    Hepatitis C-Dormant Projects (Contd..1), H1 2015 603
    Hepatitis C-Dormant Projects (Contd..2), H1 2015 604
    Hepatitis C-Dormant Projects (Contd..3), H1 2015 605
    Hepatitis C-Dormant Projects (Contd..4), H1 2015 606
    Hepatitis C-Dormant Projects (Contd..5), H1 2015 607
    Hepatitis C-Dormant Projects (Contd..6), H1 2015 608
    Hepatitis C-Dormant Projects (Contd..7), H1 2015 609
    Hepatitis C-Dormant Projects (Contd..8), H1 2015 610
    Hepatitis C-Dormant Projects (Contd..9), H1 2015 611
    Hepatitis C-Dormant Projects (Contd..10), H1 2015 612
    Hepatitis C-Dormant Projects (Contd..11), H1 2015 613
    Hepatitis C-Dormant Projects (Contd..12), H1 2015 614
    Hepatitis C-Dormant Projects (Contd..13), H1 2015 615
    Hepatitis C-Dormant Projects (Contd..14), H1 2015 616
    Hepatitis C-Dormant Projects (Contd..15), H1 2015 617
    Hepatitis C-Dormant Projects (Contd..16), H1 2015 618
    Hepatitis C-Dormant Projects (Contd..17), H1 2015 619
    Hepatitis C-Dormant Projects (Contd..18), H1 2015 620
    Hepatitis C-Discontinued Products, H1 2015 621
    Hepatitis C-Discontinued Products (Contd..1), H1 2015 622
    Hepatitis C-Discontinued Products (Contd..2), H1 2015 623
    Hepatitis C-Discontinued Products (Contd..3), H1 2015 624
    Hepatitis C-Discontinued Products (Contd..4), H1 2015 625
    Hepatitis C-Discontinued Products (Contd..5), H1 2015 626
    Hepatitis C-Discontinued Products (Contd..6), H1 2015 627
    Hepatitis C-Discontinued Products (Contd..7), H1 2015 628

    List of Figures
    Number of Products under Development for Hepatitis C, H1 2015 36
    Number of Products under Development for Hepatitis C-Comparative Analysis, H1 2015 37
    Number of Products under Development by Companies, H1 2015 38
    Number of Products under Investigation by Universities/Institutes, H1 2015 47
    Comparative Analysis by Late Stage Development, H1 2015 50
    Comparative Analysis by Clinical Stage Development, H1 2015 51
    Comparative Analysis by Early Stage Products, H1 2015 52
    Assessment by Monotherapy Products, H1 2015 175
    Assessment by Combination Products, H1 2015 176
    Number of Products by Top 10 Targets, H1 2015 177
    Number of Products by Stage and Top 10 Targets, H1 2015 177
    Number of Products by Top 10 Mechanism of Actions, H1 2015 183
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 183
    Number of Products by Top 10 Routes of Administration, H1 2015 187
    Number of Products by Stage and Top 10 Routes of Administration, H1 2015 187
    Number of Products by Top 10 Molecule Types, H1 2015 189
    Number of Products by Stage and Top 10 Molecule Types, H1 2015 189
    3-V Biosciences, Inc.
    AbbVie Inc.
    Achillion Pharmaceuticals, Inc.
    Adaptimmune Limited
    AiCuris GmbH & Co. KG
    AIMM Therapeutics B.V.
    Akshaya Bio Inc.
    Alnylam Pharmaceuticals, Inc.
    Altor BioScience Corporation
    Amarna Therapeutics B.V.
    American Gene Technologies International Inc.
    Anacor Pharmaceuticals, Inc.
    ARA Healthcare Pvt. Ltd.
    Arrowhead Research Corporation
    Ascendis Pharma A/S
    Astex Pharmaceuticals, Inc.
    Biogenomics Limited
    BioLineRx, Ltd.
    Bionor Pharma ASA
    Biotest AG
    Biotron Limited
    Bolder Biotechnology, Inc.
    Bristol-Myers Squibb Company
    Celgene Corporation
    Chiasma, Inc.
    Chugai Pharmaceutical Co., Ltd.
    Cocrystal Pharma, Inc.
    Conatus Pharmaceuticals Inc.
    Crucell N.V.
    Debiopharm International S.A.
    DEKK-TEC, Inc.
    Delpor, Inc.
    Digna Biotech, S.L.
    DiscoveryBiomed, Inc.
    Enanta Pharmaceuticals, Inc.
    F. Hoffmann-La Roche Ltd.
    Genecode AS
    GeneCure LLC
    Gilead Sciences, Inc.
    GlaxoSmithKline plc
    HanAll Biopharma Co., Ltd.
    Hanmi Pharmaceuticals, Co. Ltd.
    HEC Pharm Co., Ltd.
    Hepacyl Therapeutics, SL
    Hependo Sp. z o. o. (Ltd)
    Hetero Drugs Limited
    Humabs BioMed SA
    ImmunoBiology Ltd.
    Immunocore Limited
    Immunomedics, Inc.
    Immunotech Laboratories, Inc.
    Inbiopro Solutions Pvt. Ltd.
    Inovio Pharmaceuticals, Inc.
    Integrated BioTherapeutics, Inc.
    iTherX, Inc.
    Johnson & Johnson
    Kineta, Inc.
    Koronis Pharma, Inc.
    LG Life Sciences, Ltd.
    Ligand Pharmaceuticals, Inc.
    Meda AB
    Medivir AB
    Merck & Co., Inc.
    Microbio Co., Ltd.
    Microbiotix, Inc.
    Myelo Therapeutics GmbH
    Novartis AG
    Oncolys BioPharma Inc.
    Ono Pharmaceutical Co., Ltd.
    Peregrine Pharmaceuticals, Inc.
    Pfenex Inc.
    Pfizer Inc.
    PharmaEssentia Corporation
    Polaris Pharmaceuticals, Inc.
    Presidio Pharmaceuticals, Inc.
    Profectus BioSciences, Inc.
    Quintessence Biosciences, Inc.
    Regulus Therapeutics Inc.
    RFS Pharma, LLC
    Rodos BioTarget GmbH
    Romark Laboratories, L.C.
    Seek
    SelectX Pharmaceuticals, Inc.
    SKAU Vaccines ApS
    SomaGenics Inc.
    Sorrento Therapeutics, Inc.
    Spring Bank Pharmaceuticals, Inc.
    StemCells, Inc.
    Summit Corporation plc
    Tacere Therapeutics, Inc.
    TaiGen Biotechnology Co., Ltd.
    Therapure Biopharma Inc.
    Theravectys S.A.
    Transgene SA
    United Therapeutics Corporation
    Vakzine Projekt Management GmbH
    Vaxeal Holding SA
    VBI Vaccines
    Vertex Pharmaceuticals Incorporated
    ViroLogik GmbH
    WaterStone Pharmaceuticals, Inc.
    WhanIn Pharmaceutical Co., Ltd.
    Xenetic Biosciences plc

    Request for Sample

    Report Url https://www.reportsweb.com//hepatitis-c-pipeline-review-h1-2015&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//hepatitis-c-pipeline-review-h1-2015&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//hepatitis-c-pipeline-review-h1-2015&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments